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At least two laboratories have independently reported the synthesis of benzofuroindole compounds having potential therapeutic
implications in many disease states including those that involve smooth muscle hyperactivity. Through a series of in vitro
screenings, they demonstrated the eﬃcacy (and selectivity) of these compounds to potentiate large conductance calcium-
(Ca2+-) activated K+ (BKCa) channels, by far, the most characterized of all Ca2+-dependent K+ channels. Interestingly,
promising benzofuroindole derivatives such as compound 7 (10H-benzo[4,5]furo[3,2-b]indole) and compound 22 (4-chloro-
7-triﬂuoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid) both exhibited high bladder (versus aorta) selectivity,
making them attractive alternative treatments for bladder overactivity. In recent reports, compound 22 (LDD175 or TBIC) also
showedinhibitionofileumanduterinecontractions,indicatingmultipletargettissues,whichisnotsurprisingasBKCa channelsare
ubiquitouslyexpressedintheanimalandhumantissues.Inthispaper,theauthorsdiscussthevalueofbenzofuroindolecompounds
and the challenges that need to be overcome if they were considered as smooth muscle relaxants.
1.Introduction
Smooth muscle contraction plays a fundamental role in
regulating the functions of the hollow organs in the body
such as the blood vessels, intestines, bladder, airways, and
uterus. Dysfunctional contraction of the smooth muscles
is a key pathological feature of many diseases including
hypertension, bladder overactivity (OAB), irritable bowel
syndrome, erectile dysfunction, and asthma. Abnormal
uterinecontractionsmayalsoleadtopretermlabor,thelatter
being responsible for prenatal mortality, neonatal morbidity,
and childhood developmental disorders [1]. By and large,
smooth muscle hyperactivity disorders involve immense
social cost and ﬁnancial burden to the health services, thus,
ac o n s i d e r a b l ee ﬀort has been made to understand their
etiologies and also to develop drugs with potent smooth
muscle relaxant activities.
Contractions of all smooth muscles absolutely depend
on the presence of Ca2+ which activates the contractile
machineries [2, 3]. Elevating intracellular Ca2+, which can
be achieved by agonists (e.g., acetylcholine, oxytocin, and
prostaglandin F2α), causes smooth muscle contractions.
Acetylcholine (ACh), the main contractile transmitter in
many smooth muscle tissues (e.g., the urinary bladder
and gastrointestinal tract), activates muscarinic (M3)
receptors and raises intracellular Ca2+ levels by activating
the Gq-phospholipase C- (PLC-) inositol triphosphate
(IP3)p a t h w a y[ 4]. It is also believed that extracellular Ca2+
facilitates an increase in intracellular Ca2+ via opening of
the voltage-gated Ca2+ channels [5]. M2 receptor binding
of ACh also elevates intracellular Ca2+ through a number
of controversial mechanisms including inhibition of the
production of cyclic AMP (cAMP) [6]. In the bladder
smooth muscles, where muscarinic receptor is the primary
eﬀerent receptor, agonist-induced contraction is largely
dependent on Ca2+ entry through nifedipine-sensitive
channels and activation of the Rho-kinase pathway [7].
On the other hand, oxytocin and prostaglandin F2α act
on oxytocin and prostaglandin receptors, respectively, and
release Ca2+ from intracellular stores through stimulation of
the Gq-PLC-IP3 system [8–10]. They may also propagate the
inﬂuxofextracellularCa2+ throughvoltage-gatedL-channels
[11]. In addition, oxytocin may activate nonselective cation
channels and Ca2+-activated Cl− channels leading to depo-
larization of myometrial cells and, eventually, the opening
of voltage-dependent Ca2+ channels [2, 11]. In light of these2 Journal of Biomedicine and Biotechnology
observations, drugs that could block the eﬀects of these
agonists induce smooth muscle relaxation through some
mechanisms that could block or interfere with Ca2+ entry.
Antimuscarinic agents, those that oppose the eﬀects of ACh,
are eﬀective bladder and intestinal smooth muscle relaxants
and are well-known standard therapies for OAB and in some
formsofgastrointestinalmotilitydisorders.Inaddition,Ca2+
channel blockers (CCBs) are eﬀective OAB interventions
although they are more commonly used for hypertension
and other cardiovascular diseases. CCBs block Ca2+ entry by
binding to the L-type Ca2+ channels in the heart and smooth
muscles of the peripheral vasculature, thereby generating
vasodilation and eventually lowering blood pressure
[12]. Oxytocin antagonists, CCBs, prostaglandin synthase
inhibitors, and β-adrenergic agonists are used as tocolytics
(medications to suppress premature labor) by virtue of their
inﬂuence on lowering intracellular Ca2+ levels. β-adrenergic
agonists, alike some nonsteroidal anti-inﬂammatory drugs,
increase the level of cAMP which results in the decrease in
intracellular Ca2+ by stimulating eﬄux of Ca2+ from the cell
and also uptake by the sarcoplasmic reticulum [13].
However impressive the above-named agentsare in man-
aging abnormal smooth muscle contractions, their eﬃcacy
a n da p p l i c a t i o na r el i m i t e dd u et os o m er e p o r t e dd r u g -
induced side eﬀects. In fact, the application of these com-
pounds may exacerbate the diseases albeit only in extreme
cases [14]. Antimuscarinic drugs, although eﬀective in
inhibiting bladder and intestinal contractility, also inﬂuence
normalcontractilitythusaﬀectingnormalvoidingandexcre-
tionfunctions.Moreover,muscarinicM3 receptors are found
in the salivary glands thus severe dry mouth is expected
with the use of antimuscarinic agents [14]. The standard
tocolytics, although eﬃcacious in arresting preterm labor,
also produce serious maternal and cardiovascular or adverse
fetal side eﬀects [15, 16]. Altogether, these ﬁndings indicate
that there is a necessity to develop other smooth muscle
relaxants, preferably those that act on a diﬀerent mechanism.
Another way to counteract defective smooth muscle
contractilityistoenhancerepolarizing(potassium[K+])cur-
rents [17]. K+ channels are abundantly expressed in smooth
muscles where they play an important role in determining
and regulating the excitability of the cell by acting as an
excitability “brake.” A number of K+ channel openers have
been developed, and they showed promise in preclinical and
clinical studies for a variety of smooth muscle hyperactivity
disorders. Among them are the openers of the ATP sensitive
K+ (KATP) channels and Ca2+-activated K+ (KCa) channels.
However, as K+ channels are ubiquitously expressed in
virtually all cell types, it has been thought that K+ channel
openers may not show tissue selectivity. Indeed, the most
investigated KATP channel openers pinacidil and cromakalim
eﬀectively abolished unwanted bladder contractions without
aﬀecting normal voiding [18]. However, they also exhibited
limited bladder selectivity and inﬂuenced cardiovascular
functions [19–23].
At least two noncollaborating laboratories have reported
the synthesis of novel K+ channel openers which they
thought as eﬀective interventions for smooth muscle hyper-
activity disorders, particularly in OAB. Butera and colleagues
[24] ﬁrst reported the production of benzofuroindole ana-
logues in their continued eﬀort to develop potent bladder
relaxants with minimal hemodynamic eﬀects. These benzo-
furoindole compounds were produced by manipulating the
structureofthebenzopyran-basedantihypertensiveandpro-
totypeKATP channelopenercelikalim.Initialstructuralmod-
iﬁcations of celikalim accidentally led to the production of
the Fisher-indole product 10H-benzo[4,5]furo[3,2-b]indole
(compound 7) (Figure 1), a derivative which displayed not
only potent bladder relaxant eﬀects in in vitro screenings,
but also high bladder (versus aorta) selectivity. On the other
hand, another group produced benzofuroindole compounds
by overlaying compound 7 (see above), with BMS-204352,
a prototypical opener of one type of KCa channels, the
large conductance Ca2+-activated K+ (BKCa) channel [25].
One of the derivatives, compound 22, (4-chloro-7-triﬂuoro-
methyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid)
(Figure 1) demonstrated in vitro inhibition of bladder
contractions without inﬂuencing contractility of the blood
vessels [26]. Multiple analyses showed that the above-
mentioned benzofuroindole compounds were potent activa-
tors of the BKCa channels [24–26]. BKCa channels, relative
to other K+ channel types, have more superior biophysical,
molecular, and pharmacological properties making them
more appealing targets to achieve smooth muscle relaxation
(seebelow).Inthesucceedingsections,theattractivefeatures
of benzofuroindole compounds as smooth muscle relaxants
are described, as well as some of the concerns that need to
be addressed if they were used clinically as antispasmodics or
tocolytics.
2. Benzofuroindole Compounds,
BKCa Channels,andTheirActivators
As stated above, the ﬁrst ever synthesized benzofuroindole
analogue (compound 7) was derived from a KATP channel
opener. Thus, it came as a surprise when the compound
potently activated the BKCa channels. Accordingly, the eﬀects
of compound 7 were readily reversed by the speciﬁc BKCa
channel blocker iberiotoxin, but not by glyburide (a selective
KATP channel blocker). Furthermore, voltage clamp studies
on isolated rat bladder myocytes showed that the compound
caused an iberiotoxin-sensitive increase in hyperpolarizing
current, further intensifying its BKCa channel-potentiating
properties [24]. On the other hand, Gormemis et al. [25]
reported another set of benzofuroindole compounds that are
alsopotentBKCa channelopeners.Compound22,alongwith
other novel benzofuroindole derivatives, was shown to eﬀec-
tively potentiate cloned BKCa channels expressed in Xenopus
laevis oocytes. The ionic currents caused by compound 22
were blocked by the peptide BKCa channel blocker charyb-
dotoxin indicating selective activation of the BKCa channels
[25]. Further electrophysiological characterizations of one
thepotentderivatives,compound8(7-triﬂuoromethyl-10H-
benzo[4,5]furo[3,2-b]indole-1-carboxylic acid), showed that
it highly activated cloned BKCa channels from the extracel-
lular side independent of β subunits and regardless of the
presence of intracellular Ca2+ (for a review on BKCa channel
structure, see Figure 2). In addition, it activated native BKCaJournal of Biomedicine and Biotechnology 3
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Figure 1: Structures of compound 7 (10H-benzo[4,5]furo[3,2-b]indole) and compound 22 (4-chloro-7-triﬂuoromethyl-10H-
benzo[4,5]furo[3,2-b]indole-1-carboxylic acid).
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Figure 2: Structure and physiology of BKCa channels. (a) BKCa channels are composed of two diﬀerent subunits: the pore-forming α subunit
and the auxiliary β subunits. A functional channel is made up by the association of four α and four β1 subunits. Although a single gene
codes for α, splicing leads to variants that are diﬀerent in biophysical properties and/or intracellular localization. (b) In smooth muscles,
membrane depolarization and/or intracellular Ca2+ cause the inﬂux of Ca2+ through voltage-dependent Ca2+ channels (VDCCs). This in
turn causes a rise in intracellular Ca2+ levels and smooth muscle contraction. Increases in Ca2+ levels facilitate Ca2+ binding to ryanodine
receptors (RRs) in the sarcoplasmic reticulum (SR), which produces a localized Ca2+ release (Ca2+spark) that activates the BKCa channels.
Activation of BKCachannels causes eﬄux of K+, hyperpolarization of the cell membrane, closure of VDCC, prevention of Ca2+ entry, and
eventually smooth muscle relaxation. Adapted from Garcia et al. [27].
channels from rat hippocampus pyramidal neurons [28], a
ﬁnding which might have important clinical roles. But just
how remarkable is it when a compound is an opener of the
BKCa channels?
Some excellent reviews on the structure, pharmacology,
functions (Figure 2), and the potentiality of BKCa channels
as novel therapeutic targets have been made [29, 30].
Structurally, BKCa channels are composed of two diﬀerent
subunits: the pore-forming α subunit and the auxiliary
β subunits. Although channels formed only by four α
subunits can be functional, β subunits alter the biophysical
and pharmacological properties of homomeric channels,
including Ca2+ and voltage sensitivity and gating kinetics
[28, 31–34]. These characteristics of BKCa channels make
them appealing targets, and their activators potent therapies
for many diseases: (1) abundant distribution like other K+
channel types, (2) high conductance (∼200 pS) even at low
probability of opening, thus facilitating more eﬃcient K+
eﬄux and membrane hyperpolarization (relaxation), (3)
high sensitivity to both intracellular Ca2+ concentrations
and voltage, (4) Ca2+ independence, that is, BKCa channels
can open even in the absence of Ca2+ and the Ca2+ and
membrane potential dependence of the channels are
independent of each other [29, 30].
An u m b e ro fB K Ca channel openers, derived from nat-
ural products and from synthetic chemistry, have been de-
veloped and reported (e.g., dehydrosoyasaponin-I, maxik-
diol, NS1619, BMS-204352, 17β-estradiol, ethylbromideta-
moxifen, pimaric acid, and epoxyeicosatrienoic acids [35–
38]. These substances, however, diﬀer in properties and4 Journal of Biomedicine and Biotechnology
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Figure 3: Structures of the highly bladder (versus aorta) selective benzofuroindole compounds synthesized by Butera et al. [24].
in some respects, mechanisms of action. For instance,
dehydrosoyasaponin-I and 17β-estradiol may require β sub-
units for optimum channel potentiation [31,39], while some
compounds (e.g., dehydrosoyasaponin-I and 17β-estradiol)
may act only on the intracellular side of the channel by
being highly impermeable [40]. Unexpectedly, given the
potentiality of BKCa channel openers as future interventions
in many disease states, it is surprising that only four BKCa
channel openers have entered clinical development (NS-8,
TA-1702, BMS-223131, and BMS-204352) [27]. To the best
ofourknowledge,clinicaltrialsfortheBKCa channelopeners
NS8, BMS204352, and TA-1702 have been discontinued,
whileonlyonedrugcandidate,andolast(forthetreatmentof
asthma), remains in the early phase of clinical development
[41]. In the view of Garcia et al. [27], there is still much
validation required for BKCa channel openers to progress as
futuresmoothmusclerelaxants.NovelBKCa channelopeners
must show appropriate potency and selectivity, eﬃcacy in
preclinical disease models, and, most of all, lesser toxicity
[27].
3. Benzofuroindole Compounds,
BKCa ChannelOpenerswith Bladder
(versusAorta)Selectivity
Aside from remarkably potentiating BKCa channels from rat
bladder myocytes, benzofuroindole compounds developed
by Butera and colleagues were also shown to be highly
bladder selective with aorta/bladder IC50 ratios ranging from
8- to 46-fold. This was ascertained through organ bath
studies with isolated rat bladder and aortic rings. In their
studies, compound 15 showed to be the most bladder selec-
tive (IC50 ratio aorta/bladder = 46). The structure-activity
relationships for these compounds have been reported
a n dr e v i e w e d[ 14, 24]. By looking at the structures of
compounds 7, 14, 15 and those of the other highly bladder
selective derivatives (compounds 22, 23, and 24), bladder
speciﬁcity could be attributed to the imbedded 5,5 ring
system that is fairly tolerant of structural modiﬁcations
[14] (Figure 3). Meanwhile, dela Pe˜ na et al. [26] also
disclosed the bladder (versus aorta) selectivity proﬁle of
compound 22, the benzofuroindole analogue synthesized
by Gormemis and colleagues. In their multiple screenings,
compound22orLDD175displayed20-foldselectivityforthe
rat bladder compared with the aorta (when Emax values are
compared) [26]. What is more, compound 22 did not have
any signiﬁcant vasorelaxant activity. In vivo screenings in the
SpontaneouslyHypertensiverat(SHR), an animal model of
hypertensionalsoshowedthatcompound22didnotalterthe
rat’s hemodynamic activities. In addition, the same group
demonstrated that oral administration of compound 22
reduced voiding frequency and lengthened void intervals in
SHR, a putative animal model of OAB [42]. It is noteworthy
that these eﬀects were seen only in the SHR and not in the
normotensive strain, the Wistar Kyoto rats, a ﬁnding that
might have signiﬁcant clinical implications.
In certain disease states such as OAB, a major drawback
of current pharmacotherapies as well as those drugs in devel-
opment, is their ability to aﬀect cardiovascular activities.
KATP channel openers, compounds ﬁrst developed for OAB,
also activated KATP channels in the heart and peripheral
blood vessels and brought hemodynamic side eﬀects. For
this reason, the development of KATP drugs for OAB has
been abandoned in recent years [14]. The focus has been
shifted to other K+ channel openers, such as BKCa and the
recently identiﬁed KCNQ channels openers [14]. Compared
with KATP channels, BKCa channels are less expressed in
the heart tissue [29, 30] but are abundant in the bladder
smooth muscles and also in neuronal tissues. With regard
to their expression in neuronal tissues, BKCa activators
could then impact OAB whether the underlying etiology
is either neurogenic or myogenic in nature [14]. In fact,
it is proposed that targeting the neuronal channels could
minimize cardiovascular side eﬀects, although it might also
lead to the emergence of unwanted neuronal side eﬀects
[14].Journal of Biomedicine and Biotechnology 5
Table 1: EC50 values (concentration producing 50% of maximum
inhibition of spontaneous or agonist-induced contractions) of
compound 22 in the isolated bladder, ileum and uterus.
EC50 values (μM)
Eﬀects of compound 22
in
Bladder
[26]
Ileum
[43]
Uterus
[44]
Spontaneous
contractions n.e. 1.25 4.63
Agonist-induced
contractions
ACh (1μM) 1.25 5.01 4.37
EFS n.e. 3.16 n.t.
High k+(20mM KCI) 2.51 0.79 3.04
n.e.: no eﬀect, n.t.: not tested.
4. Compound 22 andIts Effects in
Other Smooth Muscles
BKCa channels are abundantly distributed in many smooth
muscle types such as gastrointestinal smooth muscles [41]
and the uterus [45–47] .A sn o tm u c hi sk n o w na b o u tt h e
eﬀects of benzofuroindole compounds in other tissues, an
ongoing eﬀort has been made to investigate this matter.
Compound 22 also displayed potent inhibition of both
spontaneous and agonist-induced contractions of the ileum
[43]a n du t e r u s[ 44]. EC50 values of the relaxant eﬀects of
compound 22 are shown in Table 1. While compound 22
did not have any intrinsic relaxant activity in the bladder
(suggesting its lack of eﬀect on myogenic contractions),
it signiﬁcantly inhibited spontaneous contractions of the
ileum and the uterus. However, the eﬀect of compound
22 was more demonstrated in ACh-induced contractions
of the bladder versus ileum and uterus. The detrusor was
not responsive to the eﬀects of compound 22 in electric
ﬁeld stimulation- (EFS-) induced contractions. Conversely,
the relaxative eﬀect of compound 22 in EFS-induced ileal
contraction was comparable to that induced by ACh. In
bladder and ileum strips, however, compound 22 was not
as potent as atropine, an antimuscarinic drug, in inhibiting
ACh-induced contractions [26, 43]. In the uterus, although
compound 22 relaxed oxytocin, prostaglandin F2α,a n d
ACh-induced contractions, its eﬀe c t sw e r en o ta sp o t e n ta s
those of standard tocolytics (note, however, the similarity
in the degree of potency between diclofenac and compound
22 in inhibiting PGF2α-induced contractions) [44]. Never-
theless, the eﬀects of compound 22 were all consistent with
the activation of BKCa channels, as evidenced by the counter
eﬀects of BKCa channel blockers iberiotoxin or penitrem A
[26, 43, 44] on the relaxative eﬀects of compound 22 in high
K+- (20mM KCl-) induced contractions (Table 1). Other
ion channels or contractile machineries may also be at play
considering the eﬀects of compound 22 in high-K+- (60–
80mMKCl-)inducedcontractions[26,43,44,48,49].Taken
together, these ﬁndings indicate that in addition to bladder-
relaxant activities, compound 22 also inﬂuences intestinal
and uterine contractions.
5. Concluding Remarks
Although K+ channel openers hold promise as eﬀective and
safer alternatives to many smooth muscle relaxants that are
used today, most K+ channel openers in development have
not lived up to our expectation [14]. A majority of KATP
channel openers lacked selectivity and brought unwanted
side eﬀects (e.g., cardiovascular) considered worse than
those wrought by standard antispasmodics or tocolytics.
Thus, the development of KATP channel openers has been
discontinued, and the interest was shifted to developing
other K+ channel openers that are as eﬃcacious as standard
smooth muscle relaxants, but with signiﬁcantly better side
eﬀect proﬁle. Recent years have seen great advances in our
understanding of the structure and function of existing K+
channels. Due to unmet expectations with KATP channel
openers, newer channels or associated channel proteins have
been characterized as potential drug targets. As stated above,
among those explored were the BKCa channels. While the
role of BKCa channels in the CNS is complex and still
an area of active academic research, there appears to be
a consensus on the contribution of these channels to the
regulation of smooth muscle tone [41]. In this paper, we
reviewed the contribution of benzofuroindole derivatives in
the ﬁeld that searches for ideal compounds for OAB (or
for other pathophysiologic conditions). We have stated the
remarkable proﬁles of these compounds if considered as
future OAB drug treatment. Some investigators, however,
showed the potency of a certain benzofuroindole analogue
(compound 22) to relax ileum and uterine contractions,
indicating that like other K+ channel openers, selectivity is
still an area of concern with benzofuroindole compounds.
However, it is still too early to conclude that benzofuroin-
dole analogues have no place in the roll of alternative
or safer smooth muscle relaxants. More investigations are
required to better understand their mechanics and charac-
teristics and ultimately to address their lack of selectivity.
The potency of various benzofuroindole compounds in
smooth muscle types can be compared [48]a n df r o m
there we may discover the drugs’ most appropriate clinical
application.
Finally, the worth of BKCa channel openers as “better”
smooth muscle relaxants is just proven theoretically but not
in clinical practice. Not much is known about the physiology
of BKCa channels and their activators in the disease state,
thus, whether or not a BKCa channel opener will be found
to have therapeutic utility will depend on the appropriate
counterbalance of BKCa channel activation versus other
excitatory inputs [14]. Moreover, some reported BKCa
channel openers do not satisfy some of the criteria set in
clinical tests to prove their worth as eﬀective smooth muscle
relaxants(forreviewsee[41]).Thisexplains,inpart,theslow
pace in the development of BKCa channel openers as smooth
muscle hyperactivity interventions. However, as molecular
biology and drug development techniques are getting more
and more advanced, it is plausible that, in the next few
years, concerns that limit the potential use of BKCa channel
openers (especially those that are recently characterized) will
be resolved. Therefore, the road ahead may be tedious for6 Journal of Biomedicine and Biotechnology
benzofuroindole compounds, but there is still optimism
with regard to their potential use as eﬀective smooth muscle
relaxants.
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